Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Asthma during pregnancy
Up to 40% suffer worsening of symptoms during pregnancy
- From symptom to diagnosis
Complicated renal cysts
- Atrial fibrillation
Anticoagulation after catheter ablation – for how long?
- Wound treatment and dermal defect coverage
Fish skin matrix for the treatment of complex ulcers
- Well-being of the medical profession in primary care
Findings of a nationwide survey in Switzerland
- Severe asthma and CRSwNP
Multidisciplinary collaboration between pneumology, allergology and ENT
- Myelofibrosis
New findings on the role of inflammation in pathogenesis
- Incretin mimetics for obesity and prediabetes